Executive Summary

Investment Thesis: Trulieve ($TCNNF) combines scale in US cannabis retail and wholesale with a strong cash position and positive free cash flow trends. Analysts see large upside, driven by market share gains and operational leverage, but the company still reports negative net income and ROE, and shares remain volatile. For investors, the thesis is about execution and margin recovery, not about near-term earnings certainty.

Current Price: $6.67 | Key Metric: Market Cap $1.59B | Stance: NEUTRAL

Company Overview

Trulieve Cannabis Corp operates vertically integrated cannabis businesses in multiple U.S. states, combining cultivation, processing and retail distribution. The company targets both medical and adult-use markets and emphasizes branded consumer products and a large store footprint.

Key Products & Competitive Position

Core Business: Retail dispensaries and wholesale supply to third-party retailers across licensed states.
Key Products: Flower, concentrates, edibles, tinctures, vape cartridges and branded consumer packaged goods sold under Trulieve labels.
Competitive Moat: Scale of retail footprint and supply chain integration, strong brand recognition in core markets, and an efficient distribution pipeline that can lower per-unit costs.

Recent Developments

Trulieve announced its fourth quarter and full year 2025 results conference call scheduled for February 26, 2026 after market. Management has highlighted improving same-store sales in key markets and reported robust cash and liquidity in recent filings. Sector reports for 2026 to 2035 highlight Trulieve as a key player aiming for market share gains via product differentiation.

Financial Snapshot

Market Cap$1.59B

P/B Ratio1.30

52-Week Range$4.30 - $16.35

Dividend Yield0.0%

EPS (TTM)-$0.70

ROE-10.83%

Revenue & Earnings Trends

Revenue on a trailing twelve month basis was roughly $1.19B per public data, with the company reporting continued top-line growth in several states during 2025. Despite revenue growth, net income was negative, around -$116M TTM, producing negative EPS of about -$0.70. Profit margins remain under pressure while management focuses on operational efficiencies and price/mix improvements.

Balance Sheet Highlights

Trulieve carries a robust liquidity profile for the sector, with total cash reported near $449M in recent filings and a current ratio of 6.09 which signals short-term solvency. Debt levels exist but are manageable, with total debt to equity near 69% per the latest public metrics. Positive levered free cash flow near $97.8M TTM suggests the company can invest in growth while servicing liabilities.

Valuation Analysis

Current Valuation Metrics

Forward P/EN/Avs Industry: N/A

PEG RatioN/AGrowth-adjusted

EV/EBITDA~5.0vs Historical: lower multiple

P/S Ratio~1.0vs Peers: in-line

Historical Comparison

Shares are trading far below the 52-week high of $16.35, about 59% below that peak, and near the lower half of their one-year range. Price-to-sales of roughly 1.0 is reasonable for a growth retail operator with improving cash flow, but negative earnings give limited P/E signal. Historically the stock has shown wide valuation swings tied to market sentiment and legislative catalysts.

Fair Value Estimate

Using a blended approach with an EV/EBITDA multiple of 6 to 8 applied to a normalized 2026 EBITDA estimate, and cross-checking with a 1.0x to 1.5x revenue multiple for a growth retail peer set, a mid-point fair value implies a range broadly consistent with analyst median targets near $21 but with wide uncertainty. Fair value depends critically on margin recovery and state-by-state execution, so you should view any estimate as scenario-dependent rather than precise.

Competitive Landscape

Market Position

Market Share: ~4-6% in the U.S. multi-state cannabis retail market in core regions, based on company-reported store counts and public market estimates | Ranking: Top 5 vertically integrated U.S. cannabis operators by retail footprint and revenue.

Key Competitors

$GTBIFGreen Thumb Industries, multi-state operator with strong branded SKUs and retail network.

$CCHWFCresco Labs, national footprint with emphasis on wholesale distribution and branded products.

$CRLBFCuraLeaf and other multi-state operators that compete on price and distribution scale.

Competitive Advantages

Moat 1: Extensive retail footprint provides direct customer access and repeat purchase economics.
Moat 2: Vertical integration reduces unit costs and stabilizes supply, supporting margin expansion when pricing stabilizes.
Moat 3: Strong liquidity and positive free cash flow enable investment in growth initiatives and M&A if execution remains solid.

Earnings Track Record

Last 4 Quarters: 2 beats / 1 miss / 1 pending

Recent Earnings History

Q4 2025Report expected 2026-02-26 after marketPENDING

Q3 2025Revenue $288.2M, Net Loss $12.5MMIXED

Q2 2025Smaller profit miss reportedMISS

Q1 2025Solid same-store sales in key marketsBEAT

Guidance Trend

Management has provided cautious operating-level commentary, emphasizing cost discipline and margin recovery plans. Formal EPS guidance remains limited, reflecting the uncertainty across state markets and the regulatory backdrop. Investors should watch management commentary on pricing, inventory turns and any state expansions for forward guidance revisions.

Analyst Sentiment

Consensus Rating: Strong Buy

Strong Buy: 2 Buy: 10 Hold: 1 Sell: 0

Price Targets

Low: $14.00
Mean: $21.00 (+215% upside)
High: $21.00

Recent Analyst Actions

Analysts have reiterated buy-side views in 2025 and early 2026 citing Trulieve's strong retail network and improving cash flow. Needham maintained a buy rating and a $14.50 target in mid-2024, while consensus sources later moved the mean target higher as sector sentiment improved. Watch for any changes post the February 26 earnings release, as analyst models will be updated if management signals stronger-than-expected margin progression.

Recent News & Catalysts

Key Developments

Q4 Results Release: Quarterly results and conference call scheduled for 2026-02-26, a near-term catalyst for sentiment and guidance.
Market Reports: Industry reports projecting growth over 2026-2035 name Trulieve as a key operator focused on product differentiation.
Cash & Liquidity Updates: Public filings show large cash balance near $449M and positive free cash flow, supporting M&A optionality or store investments.

Upcoming Catalysts

Next Earnings: Q4 2025 expected 2026-02-26 After Market | Key Events: Management Q&A on margin recovery, state-by-state performance, and capital allocation plans. Q1 2026 results expected 2026-05-05 After Market.

Technical Outlook

Current Price: $6.67 vs 52-Week High: $16.35 (-59.2% from high)

Trend Analysis

The stock has staged a recovery since the April 2025 low of $4.30, returning roughly 55% from that trough into February 2026. Momentum in early 2026 has picked up, evidenced by a 9.43% intraday jump to $6.67 on February 20. However, the trend remains lower from the 2025 high and the pattern suggests traders will react strongly to earnings and same-store sales commentary.

Key Levels

Resistance: $8.50, $12.00
Support: $5.00, $4.30

Bull vs Bear Case

Bull Case

Catalyst 1: Continued margin recovery from supply chain efficiencies and price stabilization could turn negative EPS to positive, driving re-rating.
Catalyst 2: Strong cash position and free cash flow enable targeted M&A and store openings, increasing revenue and scale benefits.
Catalyst 3: Analyst targets imply substantial upside if national legalization sentiment improves and distributors consolidate market share.

Bull Target: $21.00 (+215%)

Bear Case

Risk 1: Continued negative earnings and weak ROE could keep the stock depressed if pricing pressure persists in core markets.
Risk 2: Regulatory uncertainty and state-level changes could limit market expansion and keep margins volatile.
Risk 3: High beta and market sensitivity mean the stock could fall sharply on any execution miss or negative guidance.

Bear Target: $4.50 (-32%)

Risks to Consider

Valuation Risk: Negative EPS makes classic P/E based valuation unreliable and increases reliance on scenario analysis and EV/EBITDA comparisons.
Competitive Risk: Other multi-state operators may undercut pricing or expand faster, pressuring Trulieve's market share and margins.
Macro Risk: High beta at 2.58 indicates sensitivity to risk-off equity flows, which can cause large intraday and multi-week moves.
Execution Risk: Turning scale advantages into sustained profitability requires execution on store operations, inventory management and SKU optimization.

Bottom Line

Investment Verdict: NEUTRAL

Trulieve is a well-capitalized, scale operator in the U.S. cannabis market with clear upside scenarios if margins recover and same-store sales stay strong. At the same time, negative earnings and regulatory uncertainty create meaningful downside risk. If you believe in margin normalization and industry consolidation, Trulieve could be attractive. If you need consistent earnings now, this may be speculative.

Action Items for Investors

Long-term investors: Consider accumulating on weakness with a time horizon of 12 to 36 months, but size positions conservatively and stagger purchases to manage regulatory and execution risk.
Short-term traders: Trade around catalyst dates such as the February 26 earnings call and May 5 Q1 results, using stop-losses given high intraday volatility.
Risk management: Keep position size small relative to portfolio, monitor quarterly same-store sales and cash flow, and set stop levels near $5.00 support to limit downside.

What to Watch This Week

Q4 2025 earnings release, February 26, 2026 after market, and the management Q&A for guidance clarity.
Analyst model revisions and any changes to the consensus price target following the Q4 print.
State-level regulatory or retail expansion news that could materially change revenue mix or gross margins.

TCNNF: Trulieve — Growth Potential vs Valuation